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AbstrACt
Introduction Haemophilia A is a rare bleeding disorder 
caused by coagulation factor VIII (FVIII) deficiency. This is 
treated with factor VIII, conventionally using products with 
a half-life of 8–12 hours typically administered every 2–3 
days. Recombinant FVIII Fc (rFVIIIFc) represents a new 
generation of products with an extended half-life allowing 
higher FVIII levels and longer dosing interval. The efficacy 
and safety of rFVIIIFc have been established in clinical 
studies and several years of postmarketing use. However, 
there remains a need to compare treatment outcome with 
conventional products in routine clinical use.
Methods and analysis A-SURE is an ongoing, non-
interventional European study with the primary objective 
to compare the clinical effectiveness of rFVIIIFc with 
conventional factor products used for haemophilia A 
prophylaxis. Data covering a 24-month prospective 
period and a 12-month retrospective period will be 
collected. Three primary endpoints: bleeding rate, 
injection frequency and factor consumption will be 
used to evaluate treatment outcomes. Enrolment of 175 
patients on rFVIIIFc and 175 on conventional products is 
planned. All eligible patients from participating centres 
will be invited to participate. Visits and treatments 
follow routine clinical practice. Bias will be reduced by 
patient matching for age at baseline and the last weekly 
prophylaxis dose of a conventional product prior to 
baseline. Propensity scores will be calculated based on 
prognostic factors and potential confounders assessed 
at baseline and adjusted for in the estimation of the 
treatment effect.
Ethics and dissemination Study approval was 
obtained by local independent ethics committees and/or 
authorities, and informed consent from patients or their 
legal representative is a requirement for participation. 
Names of ethical committees and approval numbers 
are provided as supplementary information. The study 
results will be submitted for publication in a peer-
reviewed scientific journal and presented at scientific 
conferences.
trial registration number NCT02976753, Pre-results.
IntroduCtIon
Haemophilia A is a rare genetic disorder 
estimated to occur in 1 in 10 000 births.1 
The disease is characterised by a deficiency 
in coagulation factor VIII (FVIII) causing 
impaired haemostasis and prolonged 
bleeding episodes. Bleeding into joints can 
cause acute pain and swelling and may result 
in reduced joint range of motion, long-term 
cartilage damage and debilitating haemo-
philic arthropathy.2 As a result of bleeding 
episodes and consequent progressive joint 
damage, patients experience decreased phys-
ical functioning, pain and poor health-re-
lated quality of life.3 
Treatment for haemophilia A aims to 
prevent occurrence of bleeding episodes and 
to prevent sequelae including joint degra-
dation and pain. While on-demand treat-
ment is used for acute bleeding episodes, 
prophylaxis aim to prevent or reduce future 
bleeds. Primary prophylaxis (preventive treat-
ment initiated prior to joint damage) and 
secondary prophylaxis (prophylaxis initiated 
after the onset of joint damage) are recom-
mended for patients with moderate to severe 
strengths and limitations of this study
 ► The observational design allows the study to capture 
real-life experience.
 ► The prospective design allows the study to capture 
prespecified data.
 ► Innovative study design for comparing conventional 
and recombinant FVIII Fc prophylactic regimens in 
haemophilia A.
 ► The risk of bias due to the observational prospective 
design with a control group is a limitation.
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haemophilia A.4–7 Conventional factor products are 
either plasma derived or recombinant FVIII replacement 
products that have a circulating half-life of approximately 
8–12 hours with a typical dosing regimen of every 2–3 
days.1
Recombinant factor VIII Fc (rFVIIIFc) therapy was 
approved for the treatment of children, adolescents and 
adults with haemophilia A in Europe in 2015.8 Unlike 
conventional factor products, rFVIIIFc has an extended 
half-life, which allows for higher FVIII levels and longer 
intervals between injections or more flexible treatment 
schedules and therefore has the potential to improve 
both adherence and treatment outcomes.9 10
The efficacy and safety of rFVIIIFc have been established 
in the phase III studies: A-LONG (NCT01181128)9 and 
Kids A-LONG (NCT01458106),10 and confirmed by the 
phase III extension study, ASPIRE (NCT01454739), inves-
tigating the long-term efficacy and safety of rFVIIIFc.11 12 
Results from ASPIRE have demonstrated sustained safety 
and efficacy of rFVIIIFc, with low annualised bleeding 
rates (ABRs), over a period of up to 4 years.11 12
The lower clearance of rFVIIIFc compared with conven-
tional FVIII products has the potential to improve bleed 
protection without increasing the overall factor consump-
tion. At the same time, rFVIIIFc offers less frequent injec-
tions and increased flexibility to tailor treatment to the 
individual patient.13 14 Any differences between rFVIIIFc 
and conventional FVIII regarding bleed prevention, 
injection frequency and factor consumption should be 
further evaluated with real-world evidence and used to 
inform the haemophilia community (eg, health authori-
ties, payers, physicians and patients) to promote optimal 
patient care. Moreover, observational studies comple-
ment strictly controlled, phase III studies performed 
on highly selected patient populations since they reflect 
real-world treatment effectiveness. For these reasons, the 
A-SURE study was designed to evaluate the effectiveness 
of rFVIIIFc compared with conventional FVIII products 
in the prophylactic treatment of patients with haemo-
philia A over a 24-month prospective period.
MEthods
study design
A-SURE is a 24-month prospective, comparative, non-in-
terventional, ongoing phase IV study in males with 
haemophilia A who are receiving FVIII prophylaxis 
(figure 1). Patients from approximately 50 centres across 
Europe will participate in the study. The choice of treat-
ment is made by the patient and the investigator before, 
and independently from, the decision to include the 
patient in the study. Patients prescribed rFVIIIFc are 
enrolled in the rFVIIIFc treatment arm and matched with 
patients with similar baseline characteristics receiving 
conventional FVIII therapy. The treatment is prescribed 
according to usual clinical practice and not dictated by 
the study protocol. Prebaseline data covering a 12-month 
period will be collected retrospectively.
study objectives and endpoints
The primary objective of the A-SURE study is to evaluate 
the effectiveness of rFVIIIFc compared with conventional 
factor products in the prophylactic treatment of patients 
with haemophilia A over a 24-month prospective period 
(box 1). To assess the primary objective, three primary 
endpoints were established: (1) ABR, as assessed by local 
practice and defined as any bleeding episode during the 
trial, which requires treatment with a FVIII product. This 
can be a patient reported bleed and/or a bleed confirmed 
by the physician; (2) annualised injection frequencies, 
as assessed by prescription and (3) annualised factor 
consumption as assessed by dispensed factor product 
(box 2). The primary endpoints will be calculated for 
the 24-month prospective period. Secondary objectives 
include, for example, evaluation of the effectiveness of 
rFVIIIFc on patient-reported outcomes (PROs) and 
health economic parameters compared with conven-
tional factor during the prospective period.
Patient eligibility and recruitment
To limit bias in the selection of patients, the investiga-
tors at the participating centres are encouraged to enrol 
all eligible patients with prescribed rFVIIIFc treatment. 
Patients eligible for study participation must meet all 
inclusion criteria and none of the exclusion criteria 
(table 1). The first patient was enrolled in December 
2016 and the study is expected to end in 2020.
statistical methods
Sample size calculations for this study were based on esti-
mating the power of the study to reject null hypotheses 
of no difference between treatment groups related to the 
first two primary effectiveness outcomes, that is, ABR and 
annualised injection frequency.
Figure 1 A-SURE study design. A-SURE is a 24-month 
prospective observational study also including the collection 
of 12 months prebaseline data. The prophylactic factor 
treatment will be prescribed according to usual clinical 
practice and patients prescribed recombinant factor VIII Fc 
(rFVIIIFc) will be enrolled in the rFVIIIFc treatment arm and 
matched with patients with similar baseline characteristics 
receiving conventional coagulation factor VIII (FVIII) therapy.
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For evaluation of effect on bleeding episodes between 
the two treatments, simulations were used for power 
calculations. The simulations were based on the number 
of bleeding episodes calculated from a Poisson distribu-
tion. Assuming an average annual bleeding rate of four 
bleedings per year for conventional factor products,15 and 
an average annual bleeding rate of 3.38 for rFVIIIFc, 300 
patients (150 on each treatment) will have approximately 
85% power to reject the null hypothesis of no difference 
when using a two-sided test at 5% significance level.
With 150 patients per group, the study will also have 
85% power to reject the null hypothesis of no difference 
between treatment groups at the 5% level on annual 
injection frequency assuming a standard deviation of 35 
and a reduction of at least 12 injections per year.
To allow for dropouts, patients switching between 
groups and possible difficulties to find a matched control 
for each rFVIIIFc patient, 175 patients will be enrolled in 
the study per treatment group and thus aim for a total of 
350 patients in total.
data collection and primary analyses
Baseline data, as well as retrospective data from the past 
12 months relating to bleeds, surgeries, prescribed and 
dispensed factor product and health economics param-
eters will be collected at the time of enrolment. Clinical 
data will be collected in an electronic case report form 
and PROs will be collected using paper questionnaires 
at routine visits throughout the 24-month prospective 
period.
The primary analyses aim to estimate the effectiveness 
of rFVIIIFc by comparing ABR, annualised injection 
frequency and factor consumption to conventional factor 
products during the 24-month prospective period. The 
number and percentage of patients who had a bleeding 
episode as well as the total number of bleeding episodes 
will be described per treatment group. Comparisons 
between the two treatment groups will be based on ABR 
estimates from a negative binomial regression model 
adjusted for the propensity score, using observed time on 
each treatment as an offset term, and including treatment 
during the 24-month prospective period as a time-depen-
dent exposure. Bleeding rate prior to baseline will be 
included as a covariate to adjust for potential residual 
confounding by indication. A term for centre/region will 
also be included in the model. A negative binomial model 
will be preferred over a Poisson regression model due to 
expected overdispersion of the data. The same approach 
will be used for the supportive analyses of joint ABR and 
target joint ABR.
box 1 A-surE study objectives
Primary objective
 ► To evaluate the effectiveness of recombinant FVIII Fc (rFVIIIFc) com-
pared with conventional factor products in the prophylactic treat-
ment of patients with haemophilia A over a 24-month prospective 
period.
secondary objectives
 ► To evaluate the effectiveness of rFVIIIFc on patient-reported out-
comes (PROs), compared with conventional factor product(s) over a 
24-month prospective period.
 ► To evaluate the effectiveness of rFVIIIFc on health economic pa-
rameters, compared with conventional factor product(s) over a 
24-month prospective period.
 ► To evaluate the effectiveness of rFVIIIFc on bleeding rate, injection 
frequency and factor consumption over a 24-month prospective pe-
riod compared with conventional factor product(s) assessed retro-
spectively for patients initiating rFVIIIFc at baseline.
 ► To evaluate the effectiveness of rFVIIIFc on health economic pa-
rameters over a 24-month prospective period compared with con-
ventional factor product(s) assessed retrospectively for patients 
initiating rFVIIIFc at baseline.
 ► To evaluate the effectiveness of rFVIIIFc on PROs, by comparing 
PROs on rFVIIIFc with conventional factor treatment at baseline in 
patients initiating rFVIIIFc at baseline over a 24-month prospective 
period.
box 2 A-surE study endpoints
Primary endpoints
 ► Annualised bleeding rate (ABR).*
 ► Annualised injection frequency.†
 ► Annualised factor VIII (FVIII) product consumption (IU).‡
secondary endpoints supporting the primary objective
 ► Joint ABR (as available based on bleeding episode assessed by local 
practice).
 ► Target joint ABR (as available and based on bleeding episode as-
sessed by local practice).
secondary endpoints
 ► Change (prospectively assessed–retrospectively assessed) in ABR, 
annualised injection frequency and annualised FVIII consumption.
 ► Patient-reported outcomes:
 – Euro-QoL-5D-5L.
 – Haemophilia Activities List (HAL)/Paediatric HAL; children’s and 
parents’ version.
 – Validated Hemophilia Regimen Treatment Adherence Scale-
Prophylaxis (Veritas-PRO).
 – Treatment Satisfaction Questionnaire for Medication.
 ► Health economics endpoints:
 – Inpatient visits: number, length of stay and principal diagnosis of 
hospitalisations and any surgical procedures.
 – Outpatient visits: number of emergency room visits or number of 
outpatient clinic visits (including physical therapy, etc) and rea-
son for outpatient clinic visits.
 – Missed planned activity and productivity due to haemophilia, that 
is, the number of times and hours a patient or caregiver missed 
work or school.
Bleeding episode: a bleed that requires treatment with a FVIII product. Target 
joint: a joint in which  three   or more spontaneous bleeds have occurred within 
a consecutive  6-month   period in the last year. Euro-QoL-5D-5L: standardised 
instrument for  patient  self-reported quality of life. 
*Based on bleeding episodes assessed by local practice,
†Assessed by prescription.
‡Assessed by dispensed factor product.
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The annualised injection frequency and annualised 
factor product consumption (IU) will also be described 
per treatment group and comparisons will be based on 
estimates from generalised linear models (analyses of 
covariance) adjusted for the propensity score, centre/
region and including treatment during the 24-month 
prospective period as a time-dependent exposure. The 
factor consumption will be assessed based on the amount 
of dispensed product (from pharmacy, home delivery, 
etc). Thus, the overall consumption will include treat-
ment for bleeds. Treatment during surgery will, however, 
be collected separately in the electronic case report form.
bias and bias limitation
Several approaches have been taken to minimise bias 
in the A-SURE study. To mitigate selection bias, broad 
coverage of large centres are included. Approximately 50 
recognised treatment centres across Europe have been 
invited to participate, with each centre being encour-
aged to enrol all eligible patients prescribed rFVIIIFc. 
Because each centre comprise a population of volun-
teers, a non-response selection bias is possible, and the 
final sample may not be perfectly representative. To 
describe this potential bias, certain centre information 
will be collected (ie, type of centre according to Euro-
pean Heamophilia Network, European Haemophilia 
Treatment Centres or European Haemophilia Compre-
hensive Care Centres and country) for all contacted 
centres, and whether or not they responded and if they 
participated in the study. These data will allow compar-
ison of participating and non-participating centres. To 
identify elevated background risk factors for bias such as 
physicians selectively prescribing a certain treatment to 
a particular patient group for example, to more severely 
affected patients (confounding by indication), or that the 
presence of another factor (eg, previous inhibitors influ-
ence the treatment effect (effect modifiers), retrospective 
and baseline information will be collected). These factors 
will be used to calculate a propensity score for each 
patient which in turn will be used to adjust the negative 
binomial regression model used for estimating treatment 
effectiveness. Thus, the propensity score is the estimated 
probability of receiving a particular treatment based on 
measured relevant covariates included in the model. The 
baseline covariates of interest in the A-SURE study are: 
history of prophylactic treatment, age, weight, length, 
ABO blood type, severity of haemophilia, bleeding rate in 
the past 12 months, presence of target joints, presence of 
HIV or hepatitis C virus, history of FVIII inhibitors, factor 
VIII genotype and endogenous von Willebrand factor 
levels.
Moreover, to reduce potential differences in character-
istics between patients on different treatments, patients 
in the two treatment groups will be matched. Matching 
is based on age at baseline and the last prescribed weekly 
dose of prophylactic conventional FVIII product prior to 
baseline. The age matching uses an age range of ±3 years 
for patients <16 years and of ±5 years for patients aged ≥16 
years. However, patients aged 16 years or older should not 
be matched with patients younger than 16 years old. The 
dose matching is based on a similar prescribed weekly 
factor dose (IU) of conventional factor product for 
prophylactic treatment defined as ±20%. If a matching 
control fulfilling age and dose is not available, a patient 
with the closest age should be invited.
safety
This study is not designed to answer any safety questions. 
Therefore, only serious adverse events during rFVIIIFc 
treatment from first dose to 14 days following end of 
rFVIIIFc treatment or 14 days after the patients’ last 
study visit, whichever comes first, and non-serious adverse 
events leading to permanent discontinuation of rFVIIIFc 
will be captured. The adverse events will be reported to 
authorities in accordance with guideline on good phar-
macovigilance practices, Module VI.16
Table 1 Patient eligibility criteria
Inclusion criteria Exclusion criteria
Male patients with a diagnosis of haemophilia A. Enrolment in a concurrent clinical interventional study 
involving intake of an investigational medicinal product 
within 1 year prior to enrolment.
Received prophylactic treatment with a factor product for 
the management of haemophilia A in the 12 months prior to 
enrolment.
Previously treated with commercially available extended 
half-life FVIII products other than rFVIIIFc.
At enrolment, prescribed prophylactic treatment with rFVIIIFc or 
conventional factor product regardless of participation in the study.
Presence of FVIII inhibitors (≥0.60 Bethesda unit/mL) 
at the latest available inhibitor test using the Nijmegen 
modified Bethesda assay.
Having ≥12 months’ documented prestudy treatment data regarding 
prophylactic treatment prescriptions and bleeding episodes prior to 
the baseline visit.
Signed and dated informed consent provided by the patient or the 
patient’s legally acceptable representative.
FVIII, coagulation factor VIII; rFVIIIFc, recombinant FVIII Fc. 
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Ethics and dissemination
Where appropriate according to national regulation, the 
protocol and the informed consent form were reviewed 
and approved by local independent ethics committee 
and/or authorities as applicable before the study was 
initiated. A complete list of ethical approvals are provided 
as online supplementary material. The study results will 
be disseminated by presentation at scientific congresses 
and by publication in a peer reviewed journal.
Patient and public involvememt
There has been no public or patient involvement in the 
design of this study. The study results will be disseminated 
to the participating patients via the investigators who will 
receive the study report.
dIsCussIon
This will be the first study to provide prospective data on 
the effectiveness of prophylaxis with rFVIIIFc compared 
with conventional FVIII concentrates in patients with 
haemophilia A in routine clinical practice.
The various sources of potential bias are inherent limita-
tions of observational studies. For the A-SURE study, one 
of the risks is that more severely affected patients or less 
well-controlled patients are prescribed with a particular 
treatment to a higher extent than others (confounding 
by indication). To minimise this risk, the matching on 
age and prescribed dose were implemented in addition to 
adjustment for propensity scores. While matching based 
on these parameters may be considered quite crude there 
are very limited options to define relevant matching 
criteria in a rare disease population with haemophilia A. 
Selection bias caused by the choice of the participating 
centres is another relevant risk of bias. To minimise 
this, haemophilia treatment centres across Europe were 
invited to participate in the study. Larger centres were 
chosen to the highest extent possible to ensure a suffi-
cient patient cohort at each centre to increase the likeli-
hood of finding an appropriate matched control patient 
for each rFVIIIFc patient enrolled.
The A-SURE study is designed to have three primary 
endpoints: ABR, injection frequency and factor consump-
tion. This is to reflect the interrelation between these 
factors and to illustrate how the treatment and treatment 
outcome may be influenced by the extended half-life of 
rFVIIIFc. For a patient who is suboptimally treated with 
conventional FVIII, the treatment outcome if continuing 
conventional FVIII therapy may only be improved by 
increasing the injection frequency or the amount of 
FVIII, or both. Pharmacokinetics simulations on the 
other hand illustrate that if switching to rFVIIIFc, the 
treatment outcome may be improved without increasing 
the overall factor consumption or increasing the injec-
tion frequency or even allow less frequent injections.13 
This is due to the reduced clearance of rFVIIIFc which 
allows for increased trough levels and improved bleed 
protection. A reduced injection frequency may also 
positively impact the patient’s treatment compliance and 
quality of life.14 17 Overall, the extended circulating half-
life of rFVIIIFc improves treatment flexibility and has the 
potential to raise the standard of care for individuals with 
haemophilia A.
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